AUS
NZ
UK
CA
USA
IND
_09_15_2025_06_09_10_957293.png)
Highlights
- Ventripoint Diagnostics receives CE certification .
- The AI healthcare solution offers automated cardiac image processing.
- Certification supports commercialization efforts across the European Union.
Ventripoint Diagnostics (TSXV:VPT), an artificial intelligence healthcare company specializing in heart analysis technology, has recently achieved a significant milestone. The company’s latest product, VMS+ 4.0, has been granted the European Union’s CE certification. This approval marks a crucial step forward for the company, enabling it to expand its market reach within the EU and in other regions that recognize this certification.
AI Healthcare Technology for Cardiac Analysis
Operating in the AI healthcare sector, Ventripoint Diagnostics has developed VMS+ 4.0, an advanced tool designed for cardiac image analysis. The technology is built upon Ventripoint’s proprietary Knowledge-Based Reconstruction technology, which provides volumetric cardiac measurements that are comparable to magnetic resonance imaging (MRI). By using this approach, VMS+ 4.0 aims to offer a cost-effective and efficient alternative for healthcare providers, improving both accuracy and speed.
Streamlined User Experience and Efficiency
One of the key advancements of VMS+ 4.0 lies in its enhanced user experience. The solution includes automated image processing capabilities that streamline workflow, allowing for faster and more efficient cardiac evaluations. By reducing the time required for operators to conduct these evaluations, the technology ensures that healthcare professionals can maintain accuracy without compromising on speed, making it a valuable tool in clinical settings.
Commercialization and Market Expansion
With the recent CE certification, Ventripoint Diagnostics is now positioned to pursue further commercialization efforts in the European Union. The certification also opens doors for the company in other regions that accept this approval, expanding the potential for the solution’s adoption. Additionally, VMS+ 4.0 is already licensed as a medical device in Canada, further validating its utility and potential impact in the healthcare sector.
Regulatory Progress in North America
In addition to its presence in the European market, VMS+ 4.0 is under review by the U.S. Food and Drug Administration (FDA). This development indicates that Ventripoint Diagnostics is making strides to expand its reach beyond the European Union and Canada, aiming for a broader global footprint. The company’s previous version, VMS+ 3.2, is already in use across leading hospitals in the United States, Canada, the United Kingdom, and the European Union.
